Relmada Posts Narrower FY25 Loss, Advances NVD-01 Toward Phase 3 In Bladder Cancer

AI Briefing

• – Relmada Therapeutics reports narrower FY25 loss, advances NVD-01 toward Phase 3 trials for bladder cancer; secures $160M PIPE financing
• – NDV-01 shows strong 12-month data in bladder cancer clinical trials
• – Company's cash runway extended through 2029